Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation

NARecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 10, 2022

Primary Completion Date

June 20, 2025

Study Completion Date

September 19, 2025

Conditions
Myeloablative Allogeneic Hematopoietic Cell TransplantationIntraoral Photobiomodulation TherapyOral MucositisMucosal Ulcer
Interventions
DEVICE

THOR LX2.3 with LED Lollipop

The intraoral PBMT device will be placed inside of the mouth to deliver the therapeutic light. Each treatment is approximately 2-3 minutes in duration. PBMT will be administered daily starting from the start of conditioning through day +20, or discharge if prior to day +20, with 27 consecutive days defined as a maximum PBMT treatment duration

Trial Locations (1)

02115

RECRUITING

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

THOR Photomedicine Ltd

UNKNOWN

lead

Dana-Farber Cancer Institute

OTHER